Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 23

1.

Assessment of letrozole and tamoxifen alone and in sequence for postmenopausal women with steroid hormone receptor-positive breast cancer: the BIG 1-98 randomised clinical trial at 8·1 years median follow-up.

Regan MM, Neven P, Giobbie-Hurder A, Goldhirsch A, Ejlertsen B, Mauriac L, Forbes JF, Smith I, Láng I, Wardley A, Rabaglio M, Price KN, Gelber RD, Coates AS, Thürlimann B; BIG 1-98 Collaborative Group.; International Breast Cancer Study Group (IBCSG)..

Lancet Oncol. 2011 Nov;12(12):1101-8. doi: 10.1016/S1470-2045(11)70270-4.

2.

The advantage of letrozole over tamoxifen in the BIG 1-98 trial is consistent in younger postmenopausal women and in those with chemotherapy-induced menopause.

Chirgwin J, Sun Z, Smith I, Price KN, Thürlimann B, Ejlertsen B, Bonnefoi H, Regan MM, Goldhirsch A, Coates AS; BIG 1-98 Collaborative and International Breast Cancer Study Groups..

Breast Cancer Res Treat. 2012 Jan;131(1):295-306. doi: 10.1007/s10549-011-1741-6.

3.

Letrozole therapy alone or in sequence with tamoxifen in women with breast cancer.

BIG 1-98 Collaborative Group., Mouridsen H, Giobbie-Hurder A, Goldhirsch A, Thürlimann B, Paridaens R, Smith I, Mauriac L, Forbes J, Price KN, Regan MM, Gelber RD, Coates AS.

N Engl J Med. 2009 Aug 20;361(8):766-76. doi: 10.1056/NEJMoa0810818.

4.

Design, conduct, and analyses of Breast International Group (BIG) 1-98: a randomized, double-blind, phase-III study comparing letrozole and tamoxifen as adjuvant endocrine therapy for postmenopausal women with receptor-positive, early breast cancer.

Giobbie-Hurder A, Price KN, Gelber RD; International Breast Cancer Study Group.; BIG 1-98 Collaborative Group..

Clin Trials. 2009 Jun;6(3):272-87. doi: 10.1177/1740774509105380.

5.

Bone fractures among postmenopausal patients with endocrine-responsive early breast cancer treated with 5 years of letrozole or tamoxifen in the BIG 1-98 trial.

Rabaglio M, Sun Z, Price KN, Castiglione-Gertsch M, Hawle H, Thürlimann B, Mouridsen H, Campone M, Forbes JF, Paridaens RJ, Colleoni M, Pienkowski T, Nogaret JM, Láng I, Smith I, Gelber RD, Goldhirsch A, Coates AS; BIG 1-98 Collaborative and International Breast Cancer Study Groups..

Ann Oncol. 2009 Sep;20(9):1489-98. doi: 10.1093/annonc/mdp033.

6.

Prognostic and predictive value of centrally reviewed Ki-67 labeling index in postmenopausal women with endocrine-responsive breast cancer: results from Breast International Group Trial 1-98 comparing adjuvant tamoxifen with letrozole.

Viale G, Giobbie-Hurder A, Regan MM, Coates AS, Mastropasqua MG, Dell'Orto P, Maiorano E, MacGrogan G, Braye SG, Ohlschlegel C, Neven P, Orosz Z, Olszewski WP, Knox F, Thürlimann B, Price KN, Castiglione-Gertsch M, Gelber RD, Gusterson BA, Goldhirsch A; Breast International Group Trial 1-98..

J Clin Oncol. 2008 Dec 1;26(34):5569-75. doi: 10.1200/JCO.2008.17.0829.

7.

[Randomised phase III trial of fotemustine versus fotemustine plus whole brain irradiation in cerebral metastases of melanoma].

Mornex F, Thomas L, Mohr P, Hauschild A, Delaunay MM, Lesimple T, Tilgen W, Nguyen BB, Guillot B, Ulrich J, Bourdin S, Mousseau M, Cupissol D, Bonneterre J, de Gislain C, Bensadoun JR, Clavel M.

Cancer Radiother. 2003 Feb;7(1):1-8. French.

PMID:
12648711
8.

A prospective randomized multicentre phase III trial of fotemustine plus whole brain irradiation versus fotemustine alone in cerebral metastases of malignant melanoma.

Mornex F, Thomas L, Mohr P, Hauschild A, Delaunay MM, Lesimple T, Tilgen W, Bui BN, Guillot B, Ulrich J, Bourdin S, Mousseau M, Cupissol D, Bonneterre ME, De Gislain C, Bensadoun RJ, Clavel M.

Melanoma Res. 2003 Feb;13(1):97-103.

PMID:
12569292
9.

[Interpretation of the CA125 kinetics during first line chemotherapy of the ovarian cancer: methodological aspects and characteristic profiles].

Riedinger JM, Eche N, Basuyau JP, Daver A, Touzery C, Mayer F, Coudert B, Fargeot P, Chauffert B, de Gislain C, Zanetta S.

Ann Biol Clin (Paris). 2002 Mar-Apr;60(2):183-91. French.

10.

Results of a phase III prospective, randomised trial, comparing mitoxantrone and vinorelbine (MV) in combination with standard FAC/FEC in front-line therapy of metastatic breast cancer.

Namer M, Soler-Michel P, Turpin F, Chinet-Charrot P, de Gislain C, Pouillart P, Delozier T, Luporsi E, Etienne PL, Schraub S, Eymard JC, Serin D, Ganem G, Calais G, Maillart P, Colin P, Trillet-Lenoir V, Prevost G, Tigaud D, Clavère P, Marti P, Romieu G, Wendling JL.

Eur J Cancer. 2001 Jun;37(9):1132-40.

PMID:
11378344
11.

[Leukemia and pre-leukemic conditions occurring after treatment of breast cancer].

Cutuli B, Janvier M, de la Rochefordière A, Julien JP, Isambert N, Alzieu C, Kerbrat P, de Lafontan B, van Lemmens L, Curé H, Ganem G, Baume D, Le Mevel A, Lorthoraly A, de Gislain C, Marchal C, Chevelle C, Lauche H, Serin D.

Presse Med. 2000 Jan 29;29(3):135-8. French.

PMID:
10686962
12.

Iatrogenic risks of endometrial carcinoma after treatment for breast cancer in a large French case-control study. Fédération Nationale des Centres de Lutte Contre le Cancer (FNCLCC).

Mignotte H, Lasset C, Bonadona V, Lesur A, Luporsi E, Rodier JF, Cutuli B, Lasry S, Mauriac L, Granon C, Kerr C, Giard S, Hill C, de Lafontan B, de Gislain C, D'Anjou J, Fondrinier E, Lefeuvre C, Parache RM, Chauvin F.

Int J Cancer. 1998 May 4;76(3):325-30.

13.

[Feasability of the dose adjustment of continuous infusion administration over 120 hours of 5-fluorouracil associated with cisplatin].

Coudert B, De Gislain C, Beltramo JL, Guigues B, Mayer F, Bruchon Y, Riedinger JM, Fargeot P, Dumas M, Guerrin J.

Bull Cancer. 1996 Oct;83(10):847-52. French.

PMID:
8952635
14.

[Predictive value of the hemogram for myelotoxicity induced by the association of carboplatin-fluorouracil on the 4th day of the therapeutic regimen].

Cappelaere P, Fournier C, Rolland F, Meeus L, Domenge C, Krakowski I, De Gislain C, Chauvergne J, Dufour-Esquerre F, Pion JM, Hecquet B.

Bull Cancer. 1996 Jul;83(7):559-65. Review. French.

PMID:
8868944
15.

[Randomized placebo trial of myeloprotection with goralatide in patients with squamous cell carcinoma of the upper respiratory and digestive tracts or esophagus, treated with a carboplatin-fluorouracil combination].

Cappelaere P, Hecquet B, Rolland F, Meeus L, Domenge C, Krakowski I, De Gislain C, Chauvergne J, Dufour-Esquerré F, Carde P.

Bull Cancer. 1995 Sep;82(9):732-7. French.

PMID:
8535033
16.
17.

[Course of blood creatinine during repeated injections of cisplatin. Influence of drug combinations].

de Gislain C, Dumas M, d'Athis P, Chapuis T, Mayer F, Fargeot P, Guerrin J, Escousse A.

Therapie. 1990 Sep-Oct;45(5):423-7. French.

PMID:
2260036
18.

Influence of hydration on ultrafilterable platinum kinetics and kidney function in patients treated with cis-diamminedichloroplatinum(II).

Dumas M, de Gislain C, d'Athis P, Chadoint-Noudeau V, Escousse A, Guerrin J, Autissier N.

Cancer Chemother Pharmacol. 1990;26(4):278-82.

PMID:
2369792
19.

Evaluation of the effect of furosemide on ultrafilterable platinum kinetics in patients treated with cis-diamminedichloroplatinum.

Dumas M, de Gislain C, d'Athis P, Chadoint-Noudeau V, Escousse A, Guerrin J, Autissier N.

Cancer Chemother Pharmacol. 1989;23(1):37-40.

PMID:
2909288
20.

Influence of frusemide on cis-dichlorodiammineplatinum (II) pharmaco-kinetics.

Dumas M, d'Athis P, de Gislain C, Lautissier JL, Autissier N, Escousse A, Guerrin J.

Eur J Drug Metab Pharmacokinet. 1987 Jul-Sep;12(3):203-6.

PMID:
3436343

Supplemental Content

Loading ...
Support Center